• Markets
    • icon
  • Companies
PTX · ASX

Prescient Therapeutics Limited (ASX:PTX)

AU$0.047

 0.002 (4.444%)
ASX:Live
09/09/2024 04:10:50 PM
HALO Price Momentum HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

PTX Overview

PTX Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About PTX

Website

Prescient Therapeutics Limited

Telephone

61.3.9692.7222

Address

Level 4 100 Albert Road South Melbourne, Victoria (VIC) 3205

Description

Prescient Therapeutics Ltd. is a biopharmaceutical company, which engages in the discovery and development of novel immunotherapeutic products for the treatment of chronic infectious diseases and cancer. It develops immune therapeutics based upon its Co-X-Gene and fowlpox virus delivery technologies. The company was founded on May 22, 1986, and is headquartered in South Melbourne, Australia.

PTX Price Chart

Key Stats

Market Cap

AU$37.04M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.04 - 0.1

Trade Value (12mth)

AU$12,310.00

1 week

2.27%

1 month

9.76%

YTD

-33.82%

1 year

-37.5%

All time high

184.85

Key Fundamentals

EPS 3 yr Growth

50.00%

EBITDA Margin

N/A

Operating Cashflow

-$7m

Free Cash Flow Return

-33.50%

ROIC

-37.30%

Interest Coverage

N/A

Quick Ratio

8.10

Other Data

Shares on Issue (Fully Dilluted)

805m

HALO Sector

Healthcare

Next Company Report Date

01-Sep-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

PTX Announcements

Latest Announcements

Date Announcements

05 September 24

PTX Presentation

×

PTX Presentation

26 August 24

Appendix 4E and 2024 Annual Report

×

Appendix 4E and 2024 Annual Report

26 August 24

Appendix 4G and Corporate Governance Statement

×

Appendix 4G and Corporate Governance Statement

31 July 24

June 2024 Quarterly Update and Appendix 4C

×

June 2024 Quarterly Update and Appendix 4C

05 July 24

Initial Director's Interest Notice

×

Initial Director's Interest Notice

04 July 24

PTX appoints Dr Gavin Shepherd as Non-Executive Director

×

PTX appoints Dr Gavin Shepherd as Non-Executive Director

04 June 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

04 June 24

Notification of cessation of securities - PTX

×

Notification of cessation of securities - PTX

20 May 24

PTX invited to present at international lymphoma forum

×

PTX invited to present at international lymphoma forum

30 April 24

March 2024 Quarterly Update and Appendix 4C

×

March 2024 Quarterly Update and Appendix 4C

08 April 24

PTX100 Ph1b results to be presented at specialist congress

×

PTX100 Ph1b results to be presented at specialist congress

05 April 24

Notification of cessation of securities - PTX

×

Notification of cessation of securities - PTX

23 February 24

Appendix 4D and Half Year Financial Report

×

Appendix 4D and Half Year Financial Report

31 January 24

December 2023 Quarterly Update and Appendix 4C

×

December 2023 Quarterly Update and Appendix 4C

18 December 23

PTX-100 Spotlight Presentation

×

PTX-100 Spotlight Presentation

11 December 23

PTX-100 Ph1b results show excellent safety & efficacy in TCL

×

PTX-100 Ph1b results show excellent safety & efficacy in TCL

28 November 23

Prescient Receives $2.4 Million R&D Tax Rebate

×

Prescient Receives $2.4 Million R&D Tax Rebate

16 November 23

Chair and CEO AGM Presentation

×

Chair and CEO AGM Presentation

16 November 23

Results of Annual General Meeting

×

Results of Annual General Meeting

06 November 23

PTX-100 abstract published online on ASH website

×

PTX-100 abstract published online on ASH website

31 October 23

September 2023 Quarterly Update and Appendix 4C

×

September 2023 Quarterly Update and Appendix 4C

17 October 23

PTX results to be presented at world's largest blood meeting

×

PTX results to be presented at world's largest blood meeting

13 October 23

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

31 August 23

Section 708A Cleansing Notice

×

Section 708A Cleansing Notice

31 August 23

Application for quotation of securities - PTX

×

Application for quotation of securities - PTX

PTX Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -16.2 -21.5 -6.3 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -21.2 -23.8 3.8 Lock Lock Lock
     Yield % Lock Lock Lock Lock -4.3 -10.5 -24.2 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.03 0.03 0.02 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.02 0.03 0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock -23.1 37.7 -27.7 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 648 728 805 Lock Lock Lock
Basic m Lock Lock Lock Lock 648 728 805 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 7 10 11 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -196.0 -48.8 65.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -7 -10 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -30.8 -39.3 -10.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -7 -10 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -30.8 -39.3 -10.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -7 -9 -12 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -2 -2 -4 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -5 -7 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock -23.3 -36.9 -17.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -4 -6 -7 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 -16 12 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 16 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -4 -6 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -8.7 -43.4 -19.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 12 22 15 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 18 28 20 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -12 -22 -14 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 2 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 17 26 18 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 17 26 18 Lock Lock Lock
     Growth % Lock Lock Lock Lock -17.9 55.6 -30.7 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -29.0 -24.9 -40.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -30.5 -26.9 -45.6 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -38.0 -46.2 -49.0 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -27.5 -32.7 -37.3 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -23.2 -28.9 -33.5 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -1,086.3 N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.7 2.2 1.3 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -73.3 -84.0 -78.5 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 17.6 12.2 8.1 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 17.6 12.2 8.1 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 86.2 88.6 77.4 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -533.0 -305.5 -319.0 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -29.0 -24.9 -40.4 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -30.5 -26.9 -45.6 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -30.5 -26.9 -45.6 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 96,052.6 202,777.8 912,500.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -96,052.6 -202,777.8 -912,500.0 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

PTX Shortsell

Frequently Asked Questions

The current share price of Prescient Therapeutics Limited (PTX:ASX) is AU$0.047.
The 52-week high share price for Prescient Therapeutics Limited (PTX:ASX) is AU$0.10.
The 52-week low share price for Prescient Therapeutics Limited (PTX:ASX)? is AU$0.04.
Prescient Therapeutics Limited (PTX:ASX) does not pay a dividend.
Prescient Therapeutics Limited (PTX:ASX) does not pay a dividend.
Prescient Therapeutics Limited (PTX:ASX) has a franking level of 0.0%.
Prescient Therapeutics Limited (PTX:ASX) is classified in the Healthcare.
The current P/E ratio for Prescient Therapeutics Limited (PTX:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.